Distinction of AA vs inherited BM failure syndromes
Naveen Pemmaraju shared on X:
“Our article just out in Clinical Lymphoma Myeloma Leukemia (CLML) led by Dr Patrice Nasnason on the Detection of PNH clones that can aid in distinction of AA vs inherited BM failure syndromes.”
Source: Naveen Pemmaraju/X
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network.
He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
Authors: Patrice Nasnas, Jianhua Ling, Yoheved Gerstein, Sa A. Wang, Sanam Loghavi, Danielle Hammond, Guillermo Montalban-Bravo, Jayastu Senapati, Naveen Pemmaraju, Jessie Corredor, Sherry Pierce, Michael Roth, Farhad Ravandi, Branko Cuglievan, Tapan Kadia and Courtney D. DiNardo
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023